Agile names Altomari as president, CEO

> Agile Therapeutics has named Al Altomari, a former senior manager at Johnson & Johnson who has been serving as Agile's executive chairman, will as successor to Thomas Rossi as president and CEO, effective immediately. Rossi, who joined Agile in 2004, will serve as scientific advisor to the company. Agile release

> Durata Therapeutics has announced the formation of the company's senior leadership team with the appointments of Paul Edick as CEO, Corey Fishman as COO and Michael Dunne as CMO. Durata release

>  YM BioSciences has appointed Nick Glover as CEO to be effective at the company's annual general meeting Nov. 18. YM release

> W. Thomas Amick will become its full time CEO of Discovery Laboratories. Amick has been serving as Discovery's interim CEO since August of 2009 and has been chairman of the board since March 2007. He will continue to serve as chairman. Discovery release

> Helicos BioSciences' board of directors has appointed Ivan Trifunovich as the company's president and CEO. Helicos release

> Oligomerix's Vic Micati, a director since 2007, has been appointed chairman of the company. In addition, Jack Pasini has been appointed to the company's board of directors and as COO. Oligomerix release

> Achillion Pharmaceuticals has promoted Milind Deshpande to president of R&D, he retains his position as chief scientific officer. Mary Kay Fenton has been promoted to senior VP and retains her position as CFO. Achillion release

> One of Australia's largest CROs, Trident Clinical Research, has moved to strengthen its clinical executive with the appointment of Dr. David Fuller as the company's Australian-based CMO. Trident release

> Axxess Pharma has retained former Wyeth Laboratories employee Christopher Sequeira as medical director. Axxess release

> Catabasis Pharmaceuticals has appointed Michael Curtis to be VP, product development. Catabasis release

> Bionest Partners has announced that Sean Xinghua Hu has been appointed managing director, North America, and head, Bionest USA. Bionest release

> Athersys' board of directors unanimously voted to elect Ismail Kola as a director of the company. Athersys release

> Cytogenix has appointed Kevin Cassidy to its board of directors. Cytogenix release

> AtheroNova has announced that Alexander Polinsky, managing partner of Maxwell Biotech Venture Fund, has been named to its board of directors. AtheroNova release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.